Wall Street Analysts’ Top Stocks to Buy Trading Under $10

Photo of Lee Jackson
By Lee Jackson Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Whether you are a trader or investor, one of the keys to success is having a meaningful enough position in the stocks you own to take advantage of strong upside price movement. As we have mentioned before, many of the big Wall Street firms do not make a habit of pounding the table on stocks trading for less than $10. They are even more reluctant on stocks trading below $5, as many of those stocks are not marginable.

The good news for our readers is, because of our deep Wall Street coverage, we can scan the firms and come up with some gems that may explode down the road. Just remember, the home builders all traded in single digits after the housing market meltdown five years ago. Many of the top bank stocks also traded to single-digit status when the market imploded in the fall of 2008. The old adage “you can’t judge a book by its cover” can easily apply. Here are more stocks to buy from around Wall Street that are trading at $10 or less.

Arbor Realty Trust Inc. (NYSE: ABR) recently increased its cash position with a secondary offering of 6 million shares of stock. The company invests in multifamily and commercial real estate-related bridge loans, junior participating interests in first mortgages, mezzanine loans, preferred and direct equity, discounted mortgage notes and other real estate-related assets, as well as holds investments in mortgage-related securities and real estate property. Arbor Realty Trust is rated as a stock to buy at Deutsche Bank with a $9.50 price target. The Thomson/First Call estimate for the stock is $9.25. Investors are paid a very solid 7.2% divided. The stock closed Friday at $6.88.

BioScrip Inc. (NASDAQ: BIOS) provides home infusion, other home care services and pharmacy benefit management (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services and PBM Services. Currently six analysts rate BioScrip at Buy, but no analysts rate it at Sell or at Hold. CNBC’s Jim Cramer recently recommended the stock for a trading bounce. Jefferies considers it a stock to buy and has a $13 price target. The consensus target stands at $11, with the high target at $17. BioScrip closed Friday at $8.84.

Cott Corp. (NYSE: COT) stock has pulled back some 30% from its 52-week high of $11.25 after second-quarter market conditions were presented as “challenging.” However, the dividend was reinstated after a ten-year hiatus, and the company bought back $6 million worth of shares in the second quarter. The company mainly does business in the United States, the United Kingdom, Canada and Mexico, but it also sells beverage concentrate to 50 other countries. Deutsche Bank rates Cott as a stock to buy and has an $11 price target. The consensus is posted at $10. Investors are paid a decent 2.9% dividend. The Friday close for Cott was $7.87.

IntraLinks Holdings Inc. (NYSE: IL) is a leading global software as a service (SaaS) provider of inter-enterprise content management and collaboration solutions. It recently launched Intralinks DealNexus, the largest global deal marketplace and professional network for qualified mergers and acquisitions (M&A) professionals. Intralinks DealNexus offers a secure and confidential way for dealmakers to find and engage the best buyers or capital partners, and it is used by more than 5,000 private equity firms, corporations, investment banks and advisors to intelligently connect and exchange deal opportunities. Wunderlich rates the company a stock to buy and has a $17 price objective. The consensus target is $12.The stock closed on Friday at $8.61.

Model N Inc. (NYSE: MODN) develops applications, such as managed care and government pricing, for life science companies and channel incentives based on design wins for technology companies. The company’s customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. The company had a recent initial public offering (IPO) that traded as high as $24.80 before badly missing earnings and being taken to the woodshed. Deutsche Bank still rates it as a stock to buy and has a $12 price target. The consensus target is at $15. The stock closed Friday at $9.88.

Novavax Inc. (NASDAQ: NVAX) is a top stock to buy at Lazard. This clinical-stage biopharmaceutical company uses recombinant nanoparticle technology to develop vaccines for a wide variety of infectious diseases. The company presently has six vaccine candidates undergoing clinical trials, with a seventh (rabies) being readied for a Phase-1 study later this year. The Lazard price target for this stock is a staggering $11, far and away the highest target on Wall Street. A trade to that level would be almost a 300% gain. The consensus estimate is at $4. The stock closed Friday at $3.17.

Nuverra Environmental Solutions Inc. (NYSE: NES) may be the low-priced leader in our stocks to buy. The company’s Shale Solutions segment provides comprehensive environmental solutions for unconventional oil and gas exploration and production, including the delivery, collection, treatment, recycle and disposal of restricted environmental products used in the development of unconventional oil and natural gas fields in the Marcellus/Utica, Eagle Ford, Bakken, Haynesville, Barnett, Permian, Mississippian Lime, and Tuscaloosa Marine Shale areas. Given the huge growth of fracking for oil and gas, this could be an interesting way to play the sector. The Wunderlich price target for the stock is $5, a high on the street, while the consensus is at $3. A move to the Wunderlich target would be a 100% gain for investors. Nuverra closed Friday at $2.34.

Rite Aid Corp. (NYSE: RAD) recently blew out its numbers and the stock took off. While the company is back to profitability, it still has a large amount of debt. We recently covered the stock in depth as a possible drug store alternative for institutional investors again. Credit Suisse rates the company as a stock to buy and has a $5 price target. The consensus is posted at $4.50. Rite Aid closed Friday at $4.70, following a successful spot stock offering.

Vernaxis Inc. (NASDAQ: APPY) is an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE MarkedAPPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis. They have moved ahead with their pivotal trial enrollment, and the analyst at Canaccord Genuity rates the company as a stock to buy. Its price target for the stock is a whopping $7, the high target for the stock. A move to that level would represent a 250% move for shareholders. The consensus target is at $5.25. Vernaxis closed Friday at $1.97.

Broken IPOs, fallen angels and all sorts of special situations show up in the stocks to buy under $10 list. Again, the nice aspect, whether trading or owning these stocks for the long haul, is that investors can take a substantial position. This can go a long way if one of these stocks has a large upswing. We will continue to scan our Wall Street coverage for more top stocks to buy under $10.

Photo of Lee Jackson
About the Author Lee Jackson →

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad and diverse career, which included a stint as the creative services director at the NBC affiliate in Austin, Texas, gives him unique insight into the financial industry and world.

Lee Jackson's journey in the financial industry spans over 30 years, with nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career was marked by his presence on the sell side during pivotal Wall Street events, from the dot.com rise and bubble to the Long Term Capital Management debacle, 9/11, and the Great Recession of 2008. This is a testament to his resilience and adaptability in the face of market volatility.

Lee Jackson’s practical financial industry experience, acquired from a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing on various platforms. This unique combination allows him to shed light on the intricacies and workings of Wall Street in a way that only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618